《益普索：2026中国生物医药创新生态重塑全球肿瘤交易的未来研究报告：从星火到燎原（英文版）（17页）.pdf》由会员分享，可在线阅读，更多相关《益普索：2026中国生物医药创新生态重塑全球肿瘤交易的未来研究报告：从星火到燎原（英文版）（17页）.pdf（17页珍藏版）》请在三个皮匠报告上搜索。

1、How Chinese biopharma innovation is forging the future of global oncology deal-makingFROM SPARK TO INFERNOAdam Kaufman,MBAJP ParkJoel Sandler,PhD Ipsos|2026|all rights reservedFROM SPARK TO INFERNO:HOW CHINESE BIOPHARMA INNOVATION IS FORGING THE FUTURE OF GLOBAL ONCOLOGY DEAL-MAKINGExecutive summary

2、The paradigm shift in global pharma:The global pharmaceutical landscape is experiencing a fundamental shift as Chinese biopharmaceutical companies evolve from fast followers to innovation leaders,particularly in oncology.While several collaborations between Chinese biotechsand multinational corporat

3、ions preceded it,the 2017 partnership between Legend Biotech and Johnson&Johnson(J&J)for their anti-BCMA chimeric antigen receptor T-cell(CAR-T)therapy Carvykti(ciltacabtageneautoleucel)represented a landmark event,as it was the first in-licensed asset of Chinese origin to become an oncology blockbu

4、ster.Chinas unique development ecosystem:The convergence of world-class contract research organizations(CROs)infrastructure,accelerated regulatory timelines,accessible capital markets,and institution-led clinical research has created an unparalleled drug development engine.This ecosystem enables mor

5、e than 5,000 Chinese research and development(R&D)companies to advance from concept to clinical validation at unprecedented speed and efficiency,generating a massive pipeline of early-stage assets ripe for partnership.Identifying future opportunities:The next wave of transformative deals will likely

6、 center on combination immunotherapy approaches,particularly PD-1/4-1BB bispecificsand PD-1/IL-2 bifunctional biologics,alongside next-generation therapies for validated targets like Claudin-18.2(CLDN18.2).Companies with assets in these areas are positioned for significant value creation as the firs